Plain-English translation of NCT07555678 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining standard radiation and chemotherapy treatment with an immune-boosting drug called sintilimab can work better for anal squamous cell cancer. Anal cancer is rare, but it often comes back even after standard treatment. Researchers believe that adding this medication—which helps your immune system fight cancer—might prevent the cancer from returning and improve survival.
Even after radiation and chemotherapy, many patients with advanced anal cancer experience the cancer returning or spreading to other parts of the body. This trial exists to see if the new treatment can overcome this problem and give patients better long-term outcomes without causing more side effects.
You likely qualify if…
You likely don't qualify if…
Your participation will depend on which group you join based on your cancer stage. All participants will receive short-course radiation therapy followed by four cycles of chemotherapy (albumin-bound paclitaxel and platinum) combined with the immune medication (sintilimab). You will have regular visits to your study site for treatment, blood tests, and imaging scans to monitor how well the treatment is working and to check for side effects. The study will track how well the cancer responds to treatment and monitor your long-term health.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China